Toggle light / dark theme

Dr. Michael West at Ending Age-Related Diseases 2018 — The Reversibility of Human Aging | LEAF

Dr. Michael West, CEO of AgeX Therapeutics and Founder of Geron Corporation, discusses breakthroughs in the understanding of biological regeneration and in induced tissue regeneration, through his talk “Hayflick Rewound: Somatic Restriction, Epigenetics, and the Reversibility of Human Aging”. This talk was given at the Ending Age-Related Diseases conference in NYC. Join us at http://lifespan.io/hero

►Conference Page: https://www.leafscience.org/ending-age-related-diseases-adva…prospects/
►Subscribe for more: https://www.youtube.com/user/LifespanIO?sub_confirmation=1
►This video is presented by LEAF. Please support our work by becoming a “Lifespan Hero”: http://lifespan.io/hero

► #LifeExtension #MichaelWest #AgeX

Scientists reverse aging process in rat brain stem cells

New research, published today in Nature, reveals how increasing brain stiffness as we age causes brain stem cell dysfunction, and demonstrates new ways to reverse older stem cells to a younger, healthier state.

The results have far reaching implications for how we understand the ageing process, and how we might develop much-needed treatments for age-related diseases.

As our bodies age, muscles and joints can become stiff, making everyday movements more difficult. This study shows the same is true in our brains, and that age-related brain stiffening has a significant impact on the function of brain stem cells.

Aubrey de Grey at Ending Age-Related Diseases 2019

Today, we’re releasing another keynote from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

In his talk, Estimating the True Complexity of Comprehensive Rejuvenation, the famous Aubrey de Grey of SENS Research Foundation discussed the intricacies of creating a complete rejuvenation biotechnology framework, including the differing rates of age-related damage and the ramifications of the extensive crosstalk between different types of this damage.

Researchers discover that the rate of telomere shortening predicts species lifespan

A flamingo lives 40 years and a human being lives 90 years; a mouse lives two years and an elephant lives 60. Why? What determines the lifespan of a species? After analyzing nine species of mammals and birds, researchers at the Spanish National Cancer Research Center (CNIO) found a very clear relationship between the lifespan of these species and the shortening rate of their telomeres, the structures that protect the chromosomes and the genes they contain. The relationship is expressed as a mathematical equation, a formula that can accurately predict the longevity of the species. The study was done in collaboration with the Madrid Zoo Aquarium and the University of Barcelona.

“The telomere shortening rate is a powerful predictor of ,” the authors write in the prestigious journal Proceedings of the National Academy of Sciences (PNAS).

The study compares the telomeres of mice, goats, dolphins, gulls, reindeer, vultures, flamingos, elephants and humans, and reveals that species whose telomeres shorten faster have shorter lives.

Adam Ford Talks With Jim Mellon of Juvenescence

Today, we want to highlight an interview with billionaire investor Jim Mellon that our friend, Adam Ford of Science, Technology, and the Future, has conducted. Like us, Adam was at the Undoing Aging conference in Berlin earlier this year, and, just as we were, he was busy conducting a number of interviews with the researchers and industry thought leaders there.

Jim Mellon is an interesting figure in the industry and the cofounder of Juvenescence, a company that has been investing in a number of promising companies that are developing rejuvenation biotechnology to treat age-related diseases.

In this video, he talks about how the company formed and the investment landscape in the aging research field, and he touches upon public availability of these technologies as well as overpopulation. Jim has been closely watching the industry for some years now, and he and his company have been making a number of investments in companies that are moving towards clinical trials.

Scientists Agree on 5 Foods to Boost Brain Health and Longevity

With the rise of fad diets, “superfoods,” and a growing range of dietary supplement choices, it’s sometimes hard to know what to eat.

This can be particularly relevant as we grow older and are trying to make the best choices to minimize the risk of health problems such as high blood pressure, obesity, type 2 diabetes, and heart (cardiovascular) problems.

We now have evidence these health problems also all affect brain function: they increase nerve degeneration in the brain, leading to a higher risk of Alzheimer’s disease and other brain conditions including vascular dementia and Parkinson’s disease.

Asia’s affluent boomers are making aging aspirational

Medical tourism has some overlap with the anti-aging market, but the way these consumers are thinking about their own longevity will likely bring up new questions for providers. Middle-aged Asian consumers don’t want to buy youth, they want to buy things that make them appreciate where they are right now.


Middle-aged Asian consumers are giving the anti-aging market a run for its money.

FDA announces new policy framework for development of regenerative medicine products

Today the U.S. Food and Drug Administration announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.

The framework — outlined in a suite of four guidance documents — builds upon the FDA’s existing risk-based regulatory approach to more clearly describe what products are regulated as drugs, devices, and/or biological products. Further, two of the guidance documents propose an efficient, science-based process for helping to ensure the safety and effectiveness of these therapies, while supporting development in this area. The suite of guidance documents also defines a risk-based framework for how the FDA intends to focus its enforcement actions against those products that raise potential significant safety concerns. This modern framework is intended to balance the agency’s commitment to safety with mechanisms to drive further advances in regenerative medicine so innovators can bring new, effective therapies to patients as quickly and safely as possible. The policy also delivers on important provisions of the 21st Century Cures Act.

We’re at the beginning of a paradigm change in medicine with the promise of being able to facilitate regeneration of parts of the human body, where cells and tissues can be engineered to grow healthy, functional organs to replace diseased ones; new genes can be introduced into the body to combat disease; and adult stem cells can generate replacements for cells that are lost to injury or disease. This is no longer the stuff of science fiction. This is the practical promise of modern applications of regenerative medicine.